Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellicum Pharmaceuticals, Inc.filedCriticalBellicum Pharmaceuticals, Inc.
Publication of HK1231753A1publicationCriticalpatent/HK1231753A1/en
The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides. The technology further relates in part to therapeutic methods for inducing an immune response and treating tumors in a patient.
HK17105444.2A2014-02-142015-02-13Methods for activating t cells using an inducible chimeric polypeptide
HK1231753A1
(en)